IR/PR

- Aimedbio attended the AACR 2023 held in Orlando, Florida

- Four posters, including a poster on 'AMB302' bladder cancer preclinical results, were presented

- 'AMB302' showed safety for 30mg/kg~80mg/kg in monkey models with no known toxicity yet

- In FGFR3-TACC3 bladder cancer mouse models, 'AMB302' was shown to have a superior anti-tumor effect than Eli Lily's ADC, which was dropped during its phase 1 clinical trial

*posters are attached below:

▽ AimedBio_AACR_poster2634_AMB302-GQ1011.pdf
▽ AimedBio_AACR_poster3410_AVATASCAN_F.pdf
▽ AimedBio_AACR_poster4486_PrecisionOncologyforPediatricMalignancy.pdf
▽ AimedBio_AACR_poster3411_GliomaNextGenDrugScreening.pdf